Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.…
Could Expanded Patent Lawsuits Change The Bull Case For BioNTech (BNTX)?
Arbutus Biopharma (NASDAQ: ABUS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 4.020 USD on 20 November 2026, down 12.8% over 52 weeks. Its 52-week range is 3.500 USD to 5.448 USD: the price is 26.2% below the high and 14.9% above the low.
At a market capitalisation of 616.24M USD, it trades at 3.6 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 89% for ABUS.
Arbutus Biopharma reports return on equity of -43.7%, an operating margin of 80.1% and revenue down 43.5% year over year.
It holds more cash than debt, a net cash position of 334.18M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 5.322 USD is 32.4% above the current price. The next earnings report is expected on 29 March 2027.